Abstract: The application disclose a method, an apparatus and a system for controlling routing information advertising, which relates to the field of communications and is used for reducing the configuration complexity and reinforcing the operability. The method includes: receiving, by a control device, first routing information sent by a first forwarding device; wherein the first routing information includes an identifier of the first forwarding device; determining a first routing path according to the identifier of the first forwarding device, an identifier of a second forwarding device and a routing path group; and determining an advertising range of second routing information for the second forwarding device according to the first routing path; for enabling the second forwarding device to advertise the second routing information according to the advertising range of the second routing information.

Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.

Abstract: Embodiments of the present application disclose a method and an apparatus for determining a next hop and advertising routing information, which relate to the field of communications and are used for reducing operation complexity of a forwarding device and reducing network maintenance workload. The method for determining the next hop provided by the embodiments of the present application includes: receiving, by a control device, first routing information sent by a first forwarding device, where the first routing information includes an identifier of the first forwarding device; determining a first routing path according to the identifier of the first forwarding device, an identifier of a second forwarding device and a routing path group; and determining a next hop in second routing information for the second forwarding device according to the first routing path, where the second forwarding device is a receiver of the second routing information advertised by the control device.

Abstract: Embodiments are directed to visualizing electromagnetic (EM) particle emissions in a computer-generated virtual environment. In one scenario, a computer system accesses portions of data representing EM particle emissions emitted by a virtualized EM particle emitter. The computer system generates a particle visualization that includes at least a portion of the EM particle emissions being emitted from the virtualized EM particle emitter within the virtual environment. The particle visualization includes an indication of the EM particle emissions' interactions with other virtual or non-virtual elements in the virtual environment. The computer system then presents the generated particle visualization in the computer-generated virtual environment. In some cases, the computer system further receives user input intended to interact with virtual elements within the virtual environment.

Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.

Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

Abstract: Embodiments of the present application disclose a method and an apparatus for determining a next hop and advertising routing information, which relate to the field of communications and are used for reducing operation complexity of a forwarding device and reducing network maintenance workload. The method for determining the next hop provided by the embodiments of the present application includes: receiving, by a control device, first routing information sent by a first forwarding device, where the first routing information includes an identifier of the first forwarding device; determining a first routing path according to the identifier of the first forwarding device, an identifier of a second forwarding device and a routing path group; and determining a next hop in second routing information for the second forwarding device according to the first routing path, where the second forwarding device is a receiver of the second routing information advertised by the control device.

Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof.

Abstract: Use of a rAAV3B vector to deliver gene products to human hepatocytes is described. The rAAV3B vectors achieve high levels of transduction even in the presence of pre-existing immunity to AAV8 or AAVrh10. Compositions and treatment regimens are described. Also provided are rAAV engineered to facilitate purification and methods of purifying the AAV.

Abstract: A polyester obtained by the esterification of terephthalic acid and ethylene glycol and the polycondensation catalysed by a mixture of magnesium ethylene glycol and antimony ethylene glycol followed by granulation. In the polyester sections, the carboxyl end group is less than 15 mol/t, the mass percentage of oligomer is lower than 0.5%, and weight percentage of diethylene glycol is lower than 0.5%.

Abstract: A high-modulus low-shrinkage polyester industrial yarn obtained by subjecting a polyester to dissolution, washing and solid state polycondensation followed by spinning. The high-modulus low-shrinkage polyester industrial yarn has a dry heat shrinkage rate of 2.0±0.25% under test conditions of 177° C.×10 min×0.05 cN/dtex. The average value of the crystal volume VC of the high-modulus low-shrinkage polyester industrial yarn is larger than 230 mm3. The high-modulus low-shrinkage polyester industrial yarn has a fiber modulus of ?100 cN/dtex. The polycondensation catalyst consists of magnesium ethylene glycol and antimony ethylene glycol, which has a small thermal degradation coefficient.

Abstract: A flame-retardant polyester fiber obtained by spinning flame-retardant polyester and irradiating with ultraviolet light and having a limiting oxygen index value of greater than 30. Flame retardant 2-carboxyethylphenylphosphinic acid to improve the flame retardant properties of polyester, the use of polyester containing unsaturated double bond in UV irradiation, the double bond opens to form a crosslinking point, the formation of a certain amount of the network structure improves the heat-resistant temperature of the poly-fiber and improves the anti-dripping performance of the polyester fiber.

Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.

Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.

Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof. The compound has an effect of regulatory of bacterial quorum sensing, and is useful for preventing and/or treating a disease caused by infection of a bacterium.

Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

Abstract: A separator for an oil well produced fluid comprises a housing and a tube group arranged within the housing. The tube group includes a plurality of horizontal pipes in a layered arrangement along a vertical direction, and a plurality of vertical pipes which allows adjacent layers of the horizontal pipes to be in fluid communication with each other. The plurality of horizontal pipes shares an inlet pipe in communication with the outside of the housing, and each of the horizontal pipes has a respective outlet. The separator is configured in such a manner that the horizontal pipes in an upper layer, a middle layer, and a lower layer are respectively used as oil pipes, water pipes, and sediment pipes.

Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.

Abstract: Non-viral delivery systems comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.

Abstract: A dual vector expression system is provided for delivery of CRISPR/Cas9, sgRNA and donor templates for supplying corrected genes or gene sequences to neonatal subjects. An AAV8 system for delivery to proliferating cells such as hepatocytes is described, as are other dual AAV vector systems for targeting to other cells.